Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
This reimbursement policy describes coverage criteria and limitations for serum and cerebrospinal fluid biomarker testing used in the diagnosis and evaluation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and MOG-IgG-associated encephalomyelitis (MOG-EM) for Blue Cross Blue Shield - Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Biomarker Testing
Coverage criteria for biomarker testing
Coverage determinations for biomarker testing as described in the policy:
ANY of the following
- For individuals with atypical clinical, laboratory, or imaging features.
- For individuals with an atypical clinically isolated syndrome, including but not limited to primary progressive or relapsing-remitting courses.
- For individuals belonging to a population in which MS is less common (for example children, older individuals, or non-Caucasians).
- For individuals with insufficient clinical or imaging evidence for diagnosis.
Testing indications and assay considerations
Document summarizes recommended indications and assay considerations for CSF OCB, AQP4-IgG, and MOG-IgG testing (clinical guidance rather than billing limits):
Coding, Assay Types, and Relevant Thresholds
| No codes listed |
| FDA-approved KRONUS Aquaporin-4 Autoantibody (AQP4Ab) ELISA Assay: semiquantitative determination of autoantibodies to Aquaporin-4 in human serum; may be useful as an aid in diagnosis of NMO/NMOSD but 'is not to be used alone' and should be used with other clinical, laboratory, and radiological findings. Many laboratories use laboratory-developed tests (LDTs) regulated under CLIA; LDTs are not FDA approved/cleared but are permitted for clinical use. |
Provider Actions, Requirements, and Testing Guidance
Verify benefits; follow coverage-specific indications and exclusions
Prior authorization and coverage are subject to the member's benefit coverage at the time of the request. CSF and serum oligoclonal band (OCB) analysis MEETS COVERAGE CRITERIA for diagnosis of MS when any of the listed situations apply (atypical clinical/lab/imaging features; atypical clinically isolated syndrome including primary progressive or relapsing-remitting course; membership in populations in which MS is less common such as children, older individuals, or non‑Caucasians; or insufficient clinical or imaging evidence for diagnosis). Serum AQP4-IgG and MOG-IgG by indirect fluorescence or FACS/cell-based assays MEET COVERAGE CRITERIA only when all specified clinical, radiologic/electrophysiologic, and risk/feature conditions are met. In all other situations, serum biomarker tests for MS DO NOT MEET COVERAGE CRITERIA; ELISA, Western blot, immunohistochemistry, or other serum assays for NMOSD or MOG-EM DO NOT MEET COVERAGE CRITERIA; and CSF testing for AQP4-IgG or MOG-IgG does not meet coverage criteria for diagnosis of MS, NMOSD, or MOG-EM.
- Verify individual benefit coverage/authorization requirements prior to ordering (application of coverage criteria dependent on benefit coverage).
- CSF OCB analysis is covered only in the listed clinical scenarios (see body).
- Serum AQP4-IgG and MOG-IgG covered only when all listed clinical, imaging/electrophysiologic, and risk criteria are satisfied; prefer cell-based/FACS methods per guidance.
- Do not use ELISA, Western blot, immunohistochemistry, or other non‑covered serum assays for NMOSD/MOG-EM testing for coverage purposes.
- CSF testing for AQP4-IgG or MOG-IgG is specifically excluded from coverage for diagnosis of MS, NMOSD, or MOG-EM.
Order paired CSF + serum OCB testing when diagnosis is uncertain or atypical
Obtain CSF examination with paired serum for OCB analysis when clinical and/or brain MRI evidence for MS is insufficient, in atypical presentations (including progressive onset), or in populations where MS is less common; the International Panel states CSF testing is 'strongly recommended' in these circumstances and CSF must be paired with serum to demonstrate CSF‑unique OCBs.
- Pair CSF with a contemporaneous serum sample to confirm CSF-specific OCBs.
- Consider CSF OCB testing when initiation of long‑term disease‑modifying therapy is being considered and diagnostic certainty is needed.
- Lower threshold for CSF testing in children, older individuals, non‑Caucasians, atypical syndromes, or progressive‑onset presentations.
Use cell‑based serum assays for AQP4 and MOG testing and confirm as needed
Order serologic AQP4‑IgG and MOG‑IgG testing (preferably using cell‑based serum assays such as microscopy CBA or flow cytometry/FACS) for patients with clinical features suggestive of NMOSD or MOG‑EM (eg, severe brainstem involvement, bilateral optic neuritis, longitudinally extensive transverse myelitis, large cerebral lesions, area postrema syndrome) and in higher‑risk populations; confirmatory testing using a different assay technique is recommended when needed.
- Prefer cell‑based serum assays (microscopy CBA or flow cytometry/FACS) because they optimize autoantibody detection and have superior sensitivity/specificity.
- Avoid reliance on ELISA or indirect immunofluorescence alone; interpret low‑titer ELISA positives with caution and obtain confirmatory testing.
- Consider timing of testing (acute attack and treatment‑free interval) and avoid routine testing in progressive disease with very low pretest probability.
FDA 510(k) K161951 cited; prefer cell‑based assays despite ELISA clearance
The policy cites FDA 510(k) documentation (K161951) as part of the evidence references for AQP4 assay availability and regulatory context; an FDA‑cleared AQP4 ELISA exists but the policy emphasizes that cell‑based assays provide superior sensitivity/specificity and ELISA should not be used alone for NMOSD/MOG‑EM diagnosis.
- FDA 510(k) K161951 (2016) is referenced in the policy's bibliography.
- Even with an FDA‑cleared ELISA available, the policy and guideline panels recommend cell‑based assays for optimal detection and interpretative caution with ELISA results.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.